Skip to content

POsitioning for Esophageal Cancer Resection

POsitioning for Esophageal Cancer Resection - a Randomized Controlled TRIal (POETRI)

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02157363
Acronym
POETRI
Enrollment
47
Registered
2014-06-06
Start date
2014-06-16
Completion date
2017-02-28
Last updated
2017-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Brief summary

Open thoracoabdominal esophagectomy (TAE) is the standard curative treatment modality for resectable esophageal cancer. TAE can be achieved by positioning the patient in the supine position for the abdominal part and in a left-lateral decubitus (LLD) position for the thoracic part, or by performing both parts in a left-screwed supine position (LSS). Aim of the present study is to compare peri- and postoperative outcome variables after TAE for esophageal cancer in the two positions. POETRI is designed as a single-center, randomized controlled trial with two parallel arms including patients with resectable esophageal cancer and type I cancers of the esophagogastric junction (AEG I). Exclusion criteria are inability to tolerate surgery or both types of positioning, inability to perform an intrathoracic anastomosis, non-malignant pathologies. The primary endpoint is operating time. Secondary endpoints are morbidity, lymph node yield, pulmonary function, pain control and wound healing assessed during a follow-up of 3 months. POETRI is a single-center, randomized controlled trial to evaluate different positioning and thoracic access during radical open thoracoabdominal esophagectomy for patients with resectable esophageal cancer.

Interventions

PROCEDURERepositioning
PROCEDURESingle positioning

Sponsors

Technische Universität Dresden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Newly diagnosed, non-metastatic esophagus cancer (squamous or adenocarcinoma) or AEG I tumors requiring curative thoracoabdominal esophagectomy with intrathoracic anastomosis of a gastric tube immediately after diagnosis or after neoadjuvant treatment * Patients are considered fit for surgery by a local interdisciplinary team of surgeons, medical oncologists and anesthesiologists (ECOG performance status of 0,1, or 2). * Age ≥ 18 years * Written informed consent

Exclusion criteria

* Preoperative established indication for colon interposition or cervical anastomosis * Preoperative diagnosed tracheo-esophageal fistula * History of right thoracotomy or prior lung surgery * Physical inability of the described intraoperative patient positioning * Non-malignant esophageal pathology or other malignancies except squamous or adenocarcinoma * Planned laparoscopic or thoracoscopic surgical approach * Patients not eligible for TAE (ASA ≥ 4)

Design outcomes

Primary

MeasureTime frameDescription
operating timeThe endpoint is assessed at the end of the operation (finishing of all wound dressings) on the day of operation.Operating time is defined from the start of patient positioning until final closing and dressing of all wounds.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026